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superiority in terms of safety and efficacy among drugs. This bulletin intends to
improve health care efficiency when it points out the differences on treatment
costs among the drugs. The objective of this study is to analyze all editions of The
Health and Economics Bulletin available onANVISAwebsite.METHODS:Datawere
collected from editions of Health and Economics Bulletin published since August
2009 (month of launch) until January 2012. The variables considered were: number
and type of diseases, therapeutic classes, active substance, drugs and treatment
costs. RESULTS: Seven editions of the bulletin were published and each number
addressed a different disease such as osteoporosis, glaucoma, gastroesophageal
reflux, arterial hypertension, epilepsy, dyslipidemia and erectile dysfunction. In
total, 11 therapeutic classes were evaluated which comprises biphosphonates and
statins on osteoporoses and dyslipidemia editions, respectively. A total of 27 active
substances and 51 drugs were assessed, including generics, similars and brand
drugs. Fifty-one costs of treatment were performed which demonstrated consid-
erable differences between drugs prescribed for the same disease. For example, on
the arterial hypertension edition, it was found 1811% of difference on treatment
costs between the most expensive and the lowest cost drugs although they have
similar safety and efficacy levels, based on scientific evidences. CONCLUSIONS:
The Health and Economics Bulletin is an important information tool and was elab-
orated to improve the critical view of health care decision-makers and patients.
Considering differences of treatment costs among drugs that have the same safety
and efficacy, they can select the drugs more efficiently.
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OBJECTIVES: Fewer than 100 US hospitals have all-inclusive hybrid operating room
(HOR) suites (ECRI, 2010), although this is increasing at a current annual growth rate
(CAGR) of 15% (Hankel, 2011). The benefits inherent in utilization of the hybrid
approach are substantial, yet remain largely theoretical, given the limited preva-
lence of HORs. Recent HOR technological innovations, including significant im-
provements in image quality, greater detector flexibility and angulation, and better
mobile and floor-mounting options, have driven demand for clinical and economic
data to support the initial investment required. In this study, we reviewed existing
literature on the clinical and economic value offered by HOR suites. METHODS: A
systematic review of peer reviewed literature published between 2006 and 2011
was conducted. Descriptions of the clinical, economic, and workflow benefits of
HOR programs were incorporated into the review. The review was augmented by a
search of gray literature, clinical trials and industry market research databases, as
well as relevant congress proceeding documents. Articles were screened for rele-
vance and included if they incorporated elements of HOR outcomes, cost drivers,
cost-effectiveness, or adoption drivers. RESULTS:The literature documents tangible
advantages of an HOR approach from clinical, treatment facility and payer perspec-
tives. For example, the data suggest that enabling interventional radiologists and sur-
gical specialists to collaborate in real timemay decrease required OR treatment times
by almost 30%. Other HOR primary cost drivers are associated with room installation,
resource use efficiency, and infection control. Direct comparative data, however, is
lacking in key areas. CONCLUSIONS: Our data suggests that there are clear work-
flow, clinical, and economic benefits to adopting hybrid operating rooms and pro-
cedures. Health care decision makers will benefit from detailed reviews of HOR
clinical and economic value to determine appropriate reimbursement schemes as
well as to inform investment decisions. More research is needed to establish the
appropriate approach to compare HOR versus segregated approaches.
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OBJECTIVES: According to 2010 Bureau of National Health Insurance, Department
of Health in Taiwan, drugs costs accounted for a large proportion in health care
expenditures. On the other hand, many drugs are discarded every day from the
ShuangHoHospital drug’s recycling bins. Some of themare high-priced, unopened
and unused such as Spiriva®, Plavix®, etc. It shows that among all of the health
insurance reimbursements for medications, 25% discarded. This study is to ana-
lyze the main reasons for people discarded drugs. METHODS: In order to under-
stand the possible reasons of discarding drugs, we using questionnaires for people
who may discard or has discarded drugs. At the same time, also recording the
drug’s name and its quantity in the Shuang Ho Hospital drug’s recycling bins. The
122 questionnaires were distributed, of which 112 copied were valid, 10 copied
were invalid. We used SPSS statistical software to analyze the questionnaire re-
sults. We recorded the quantity of discarded drugs in drug’s recycling bins from
Sept.26.2011 to Oct.21.2011, classified these discarded drugs into several classes.
RESULTS: According the questionnaire results, the most likely cause for people to
discard drugs can be divided into three main reasons: misconceptions (including
fear of drug’s side effects , self-withdrawal and worry about health foods may
contain bad ingredients), forget the medication and drug deterioration (including
not pay attention to the expiration date and improper preservation). The average
weight of drugs from recycling bin is 3.76 kg / day, of which gastrointestinal drugs,
cardiovascular drugs, analgesics and hypoglycemic drugs (9.49%) are the top four
classes. CONCLUSIONS:When we figure out the main reason for people discarded
drugs, we can do something to reduce the discarded drug’s quantity more effec-
tively,, and finally, drugs will not being wasted, health care insurance in Taiwan is
expected to save about NT $ 30 billion per year
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OBJECTIVES:We previously highlighted the importance of disease-specific data in
understanding growth in healthcare spending. This update presents more recent
data and decomposes the drivers of spending growth into price, utilization, and
disease prevalence changes. METHODS: US employer health care spending was
estimated using claims data from employer sponsored health plans from 2004 and
2009 (to be updated to 2010 for presentation). Claims were assigned to disease-
specific episodes using the Thomson Reuters Medical Episode Grouper (MEG). Data
were projected using sampling weights derived from the Medical Expenditure
Panel Survey and 5-year growth in spending was decomposed into growth in dis-
ease prevalence, resource consumption per disease, and medical care price level.
RESULTS:Annual spending datawere analyzed for 107 employerswith 11.5million
health plan members in 2004 and 143 employers with 18.0 million members in
2009. Over these 5 years spending permember per year grew 34% overall, 11% after
inflation adjustment. The top 50 disease categories (out of 560) accounted for 52%of
spending in 2009. Prevalence of disease-specific treatment grew for 42 of 50 cate-
gories, led by obesity (93%), renal failure (91%), and complications of medical and
surgical care (43%). Overall, growth in prevalence drove more than 90% of the
inflation-adjusted spending increase. Resource use per patient grew in 27 of the top
50 diseases, led by dyslipidemia (106%), multiple sclerosis (57%), and osteoarthritis
except spine (42%). However, other diseases showed declines and overall intensity
of resource use grew only 2% over 5 years. CONCLUSIONS:Apart frommedical care
price inflation, the major driver of growth in employer health care spending is
increased prevalence of treated disease, led by obesity and its consequences. A
secondary factor is increased intensity of resource use in those diseases targeted by
innovation in biologic therapies and surgical devices.
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OBJECTIVES: The American Recovery and Reinvestment Act of 2009 includes an
estimated $27 billion over 10 years to support adoption of electronic health records
(EHRs). This includes the Health Information Technology (HIT) for Economic and
Clinical Health Act of 2009, which promotes meaningful use of HIT through Medi-
care and Medicaid EHR Incentive Programs. In November 2011, the United States
(US) Department of Health and Human Services released a report showing adop-
tion of HIT doubled in two years. The objective of this review was to examine the
impact of EHR and computerized physician order entry (CPOE) on health care
efficiency.METHODS: A review of published original research in the United States
was conducted in PubMed for years 2007 through 2011. The number of studies
reporting efficiencies and inefficiencies, setting of care, and areas of efficiency and
inefficiency were examined. RESULTS: A total of 18 studies were reviewed: 13 EHR
or EHR/CPOE and 5 CPOE only. Settings of care included the hospital inpatient
(n6), outpatient clinic/practice (n6), emergency department (n3), surgical cen-
ter (n2), and assisted-living facility (n1). All but one study reported efficiencies
in at least one area. Efficiencies from EHR or EHR/CPOE were reported in decreased
physician/staff time (n6), increased patient volume (n3), decreased length of
stay (n3), increased provider productivity (n2), decreased tests/procedures or-
dered (n1), and decreased time to diagnosis (n1). Efficiencies from CPOE were
observed in decreased order processing/verification time (n3), decreased physi-
cian/staff time (n1), and decreased time to medication administration (n1). In-
efficiencies from one CPOE study were reported in increased prescribing time.
Three of the EHR or EHR/CPOE studies also reported inefficiencies. Some factors
that contributed to inefficiencies included complex/acute cases and the level of
EHR implementation. CONCLUSIONS: EHR implementation has the potential to
improve efficiencies in various practice settings. Further investigation iswarranted
to examine factors contributing to inefficiencies.
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OBJECTIVES: The product promotional advertisements of pharmaceutical compa-
nies in scientific journals have the advantage of reaching to highly focused group of
doctors. The specificity of these advertisements also demands for use references to
support advertising claims which creates a niche speciality, evidence based adver-
tising. The objective of the study is to assess the references pertaining to scientific
advertisements with regard to pharmacoeconomics and humanistic outcomes ev-
idence usage.METHODS: A cross sectional study was designed to assess the use of
pharmacoeconomics and humanistic evidences use in product promotional adver-
tisements in scientific journals. For the purpose of study 14 journals, published
between January, 2010 and December, 2010 which contain advertisements were
screened. These journalswere searched for advertisements and quoted references.
All the quoted references from these advertisementswere collected and examined.
The classification of references is done based on source as journal articles, books,
A22 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
